Kim Min Kyoung, Song Haengseok, Lyu Sang Woo, Lee Woo Sik
CHA Fertility Center Gangnam, CHA University School of Medicine, Seoul, Republic of Korea.
Department of Biomedical Science, CHA University, Seongnam, Republic of Korea.
Clin Exp Reprod Med. 2022 Sep;49(3):168-174. doi: 10.5653/cerm.2022.05407. Epub 2022 Aug 31.
Refractory thin endometrium and recurrent implantation failure are among the most challenging infertility-related factors hindering successful pregnancy. Several adjuvant therapies have been investigated to increase endometrial thickness and the pregnancy rate, but the treatment effect is still minimal, and for many patients, these treatment methods can be quite costly and difficult to approach. Platelet-rich plasma (PRP) is an autologous concentration of platelets in plasma and has recently been elucidated as a better treatment option for these patients. PRP is rich in cytokines and growth factors, which are suggested to exert a regenerative effect at the level of the injured tissue. Another advantage of PRP is that it is easily obtained from the patient's own blood. We aimed to review the recent findings of PRP therapy used for patients with refractory thin endometrium and recurrent implantation failure.
难治性薄型子宫内膜和反复种植失败是阻碍成功妊娠的最具挑战性的不孕症相关因素。已经研究了几种辅助疗法来增加子宫内膜厚度和提高妊娠率,但治疗效果仍然微乎其微,而且对许多患者来说,这些治疗方法可能成本很高且难以实施。富血小板血浆(PRP)是血浆中血小板的自体浓缩物,最近已被证明是这些患者更好的治疗选择。PRP富含细胞因子和生长因子,这些因子被认为在受损组织水平上发挥再生作用。PRP的另一个优点是它很容易从患者自身血液中获取。我们旨在综述用于难治性薄型子宫内膜和反复种植失败患者的PRP治疗的最新研究结果。